منابع مشابه
Photodermatosis secondary to hydroxyurea.
To cite: Yanamandra U, Sahu KK, Malhotra P, et al. BMJ Case Rep Published online: [please include Day Month Year] doi:10.1136/ bcr-2014-205974 DESCRIPTION A middle aged Southeast-Asian man, recently diagnosed with chronic myeloid leukaemia (Philadelphia positive on FISH), was started on cytoreductive therapy with hydroxyurea due to high leucocyte count (130 000/mL). The patient had no history o...
متن کاملA Case of Longitudinal Melanonychia Secondary to Hydroxyurea
Melanonychia commonly appears as a longitudinal band, starting from the matrix and extending to the tip of the nail plate. Less often it presents a transverse band or may inolve whole nail plate. Cutaneous side effects of hydroxyurea are described in 13% of patients including increased pigmentation, hyperkeratosis, skin atrophy, xerosis, lichenoid eruptions, palmar and plantar keratoderma, cuta...
متن کاملHydroxyurea sensitizes glioblastoma to temozolomide
Glioblastoma (GBM) is the most common and most aggressive primary malignant brain tumor. Standard-of-care treatment involves radiation, chemotherapy (temozolomide; TMZ), and maximal surgical resection of the tumor. The 5-year survival rate of patients with GBM is <10%, a colossal failure that has been partially attributed to intrinsic and/ or acquired resistance to TMZ. Here we sought to identi...
متن کاملENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
BACKGROUND Hydroxyurea (HU) is the only disease-modifying medication for patients with sickle cell disease (SCD). HU can reduce SCD-related complications but only 35% to 50% of pediatric patients adhere to HU at the rates achieved in clinical trials and this limits its clinical effectiveness. Mobile Directly Observed Therapy (Mobile DOT) is a pilot-tested, electronic, multidimensional, HU adher...
متن کاملFetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.
Hydroxyurea (HU) can increase fetal hemoglobin (HbF) in sickle cell anemia (HbSS). To identify determinants of the HbF response, we studied 150 HU-treated patients grouped by quartiles of change in HbF from baseline to 2 years. Half of the HU-assigned patients had long-term increments in HbF. In the top two quartiles, HbF increased to 18.1% and 8.8%. These patients had the highest baseline neut...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Case Reports
سال: 2014
ISSN: 1757-790X
DOI: 10.1136/bcr-2014-205974